Literature DB >> 21233512

Progress and problems in understanding and managing primary Epstein-Barr virus infections.

Oludare A Odumade1, Kristin A Hogquist, Henry H Balfour.   

Abstract

Epstein-Barr virus (EBV) is a gammaherpesvirus that infects a large fraction of the human population. Primary infection is often asymptomatic but results in lifelong infection, which is kept in check by the host immune system. In some cases, primary infection can result in infectious mononucleosis. Furthermore, when host-virus balance is not achieved, the virus can drive potentially lethal lymphoproliferation and lymphomagenesis. In this review, we describe the biology of EBV and the host immune response. We review the diagnosis of EBV infection and discuss the characteristics and pathogenesis of infectious mononucleosis. These topics are approached in the context of developing therapeutic and preventative strategies.

Entities:  

Mesh:

Year:  2011        PMID: 21233512      PMCID: PMC3021204          DOI: 10.1128/CMR.00044-10

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  210 in total

1.  The clinical manifestations of infectious mononucleosis: a report of two hundred cases.

Authors:  R J HOAGLAND
Journal:  Am J Med Sci       Date:  1960-07       Impact factor: 2.378

2.  Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells.

Authors:  Donna Hochberg; Tatyana Souza; Michelle Catalina; John L Sullivan; Katherine Luzuriaga; David A Thorley-Lawson
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 3.  Persistence of the Epstein-Barr virus and the origins of associated lymphomas.

Authors:  David A Thorley-Lawson; Andrew Gross
Journal:  N Engl J Med       Date:  2004-03-25       Impact factor: 91.245

Review 4.  Clinical inquiries. What test is the best for diagnosing infectious mononucleosis?

Authors:  Amy Trelease Bell; Barbara Fortune; Robert Sheeler
Journal:  J Fam Pract       Date:  2006-09       Impact factor: 0.493

5.  Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults.

Authors:  Michel Moutschen; Philippe Léonard; Etienne M Sokal; Françoise Smets; Michèle Haumont; Pasqualina Mazzu; Alex Bollen; Francoise Denamur; Pascal Peeters; Gary Dubin; Martine Denis
Journal:  Vaccine       Date:  2007-04-18       Impact factor: 3.641

6.  Measurement of heterophil antibody and antibodies to EB viral capsid antigen IgG and IgM in suspected cases of infectious mononucleosis.

Authors:  J M Blake; J M Edwards; W Fletcher; D A McSwiggan; M S Pereira
Journal:  J Clin Pathol       Date:  1976-09       Impact factor: 3.411

7.  Infectious mononucleosis in middle age.

Authors:  P G Auwaerter
Journal:  JAMA       Date:  1999-02-03       Impact factor: 56.272

8.  Skin rash with infectious mononucleosis and ampicillin.

Authors:  B M Patel
Journal:  Pediatrics       Date:  1967-11       Impact factor: 7.124

9.  Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI.

Authors:  K W Moore; P Vieira; D F Fiorentino; M L Trounstine; T A Khan; T R Mosmann
Journal:  Science       Date:  1990-06-08       Impact factor: 47.728

10.  Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis.

Authors:  Suzanne L Elliott; Andreas Suhrbier; John J Miles; Greg Lawrence; Stephanie J Pye; Thuy T Le; Andrew Rosenstengel; Tam Nguyen; Anthony Allworth; Scott R Burrows; John Cox; David Pye; Denis J Moss; Mandvi Bharadwaj
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

View more
  111 in total

Review 1.  Infectious Mononucleosis.

Authors:  Samantha K Dunmire; Kristin A Hogquist; Henry H Balfour
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

2.  Chest pain in a young patient: an unusual complication of Epstein-Barr virus.

Authors:  Lavanya Raman; Krishnaraj Sinhji Rathod; Rajesh Banka
Journal:  BMJ Case Rep       Date:  2014-03-31

3.  Performance of two commercially available automated immunoassays for the determination of Epstein-Barr virus serological status.

Authors:  J Lupo; R Germi; T Semenova; M Buisson; J M Seigneurin; P Morand
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

Review 4.  Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications.

Authors:  Jiezhong Chen
Journal:  World J Virol       Date:  2012-12-12

5.  Idiopathic pulmonary fibrosis lung transplant recipients are at increased risk for EBV-associated posttransplant lymphoproliferative disorder and worse survival.

Authors:  Carlo J Iasella; Spencer A Winters; Abigail Kois; Jaehee Cho; Stefanie J Hannan; Ritchie Koshy; Cody A Moore; Christopher R Ensor; Elizabeth A Lendermon; Matthew R Morrell; Joseph M Pilewski; Pablo G Sanchez; Daniel J Kass; Jonathan K Alder; S Mehdi Nouraie; John F McDyer
Journal:  Am J Transplant       Date:  2020-01-22       Impact factor: 8.086

6.  The prognostic impact of RAP2A expression in patients with early and locoregionally advanced nasopharyngeal carcinoma in an endemic area.

Authors:  Ying-En Lee; Hong-Lin He; Tzu-Ju Chen; Sung-Wei Lee; I-Wei Chang; Chung-Hsi Hsing; Chien-Feng Li
Journal:  Am J Transl Res       Date:  2015-05-15       Impact factor: 4.060

7.  Epstein-Barr virus replicating in epithelial cells.

Authors:  Lindsey M Hutt-Fletcher
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-10       Impact factor: 11.205

Review 8.  The molecular march of primary and recurrent nasopharyngeal carcinoma.

Authors:  Nicholas J Campion; Munira Ally; Bernhard J Jank; Jahangir Ahmed; Ghassan Alusi
Journal:  Oncogene       Date:  2021-01-21       Impact factor: 9.867

9.  The interplay between local immune response and Epstein-Barr virus-infected tonsillar cells could lead to viral infection control.

Authors:  Aldana G Vistarop; Melina Cohen; Fuad Huaman; Lucia Irazu; Marcelo Rodriguez; Elena De Matteo; María Victoria Preciado; Paola A Chabay
Journal:  Med Microbiol Immunol       Date:  2018-07-25       Impact factor: 3.402

10.  Evaluation of the Architect Epstein-Barr Virus (EBV) viral capsid antigen (VCA) IgG, VCA IgM, and EBV nuclear antigen 1 IgG chemiluminescent immunoassays for detection of EBV antibodies and categorization of EBV infection status using immunofluorescence assays as the reference method.

Authors:  Isabel Corrales; Estela Giménez; David Navarro
Journal:  Clin Vaccine Immunol       Date:  2014-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.